DSIP (5mg Vial) Dosage Protocol

DSIP (5 mg Vial) Dosage Protocol

Quickstart Highlights

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide (9 amino acids) first isolated from rabbit brain tissue and studied for its effects on sleep architecture and stress modulation[1][2]. Research indicates DSIP may promote delta-wave (slow-wave) sleep, modulate cortisol and ACTH levels, and exhibit stress-protective properties[3][4]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
  • Typical daily range: 100–300 mcg once daily (gradual titration); advanced up to 500 mcg.
  • Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
DSIP Vial

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Week 1 100 mcg 6 units (0.06 mL)
Week 2 150 mcg 9 units (0.09 mL)
Week 3 200 mcg 12 units (0.12 mL)
Weeks 4–8 250–300 mcg 15–18 units (0.15–0.18 mL)

Frequency: Inject once daily subcutaneously, typically in the evening before bedtime[5][6]. For ≤10-unit (≤0.10 mL) administrations (Weeks 1–2), consider 30- or 50-unit insulin syringes for improved readability.

Advanced / Extended Approach

Week Daily Dose (mcg) Units (per injection) (mL)
Week 5 350–400 mcg 21–24 units (0.21–0.24 mL)
Weeks 6–8+ 400–500 mcg 24–30 units (0.24–0.30 mL)

Note: Advanced dosing (beyond 300 mcg) is based on anecdotal experience; formal human studies have primarily used doses up to ~300 mcg daily[7]. Use the minimum effective dose and increase only if needed.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–12 week daily protocol with gradual titration.

  • Peptide Vials (DSIP, 5 mg each):

    • 8 weeks at ~200 mcg/day avg ≈ 2–3 vials
    • 12 weeks at ~200 mcg/day avg ≈ 3–4 vials
    • 12 weeks at ~300 mcg/day avg ≈ 5–6 vials
  • Insulin Syringes (U-100):

    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

    • 3 vials: 9 mL → 1 × 10 mL bottle
    • 5 vials: 15 mL → 2 × 10 mL bottles
    • 6 vials: 18 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
DSIP Vial
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Support healthy sleep architecture and stress modulation over time[3][4].
  • Schedule: Daily subcutaneous injections for 4–8 weeks (extend to 12 weeks if desired).
  • Dose Range: 100–300 mcg daily with gradual titration; advanced up to 500 mcg.
  • Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

  • Start: 100 mcg daily; increase by ~50 mcg every 1–2 weeks as tolerated.
  • Target: 250–300 mcg daily by Weeks 4–8.
  • Frequency: Once per day (subcutaneous), typically before bedtime.
  • Cycle Length: 4–8 weeks; optional extension to 12 weeks with periodic breaks.
  • Timing: Evening administration preferred; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[8].
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~4 weeks and avoid freeze–thaw[9].
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • Some research suggests DSIP effects may persist for multiple nights after dosing[2]; adjust frequency as needed.

How This Works

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) was first characterized in 1977 as a sleep-modulating factor isolated from rabbit brain[1]. Mechanistic studies suggest DSIP may influence sleep by modulating GABAergic transmission and interacting with opioid receptor systems[10]. Research indicates it can increase delta-wave (slow-wave) sleep duration without significantly altering REM sleep architecture[3]. Beyond sleep, DSIP has demonstrated stress-protective and adaptogenic properties in various models, potentially through modulation of the hypothalamic-pituitary-adrenal axis[4][11].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

  • May promote deeper, more restorative slow-wave sleep and improve subjective sleep quality[3][5].
  • Research suggests potential stress-protective and anxiolytic-like effects[4][11].
  • Some studies indicate DSIP does not induce pharmacological tolerance with continued use[2].
  • Generally well tolerated in human studies; occasional mild injection-site reactions may occur with subcutaneous administration.
  • Limited long-term safety data; periodic breaks are recommended as a precaution[6].

Lifestyle Factors

Complementary strategies for best outcomes.

  • Maintain consistent sleep-wake schedules to reinforce circadian rhythms.
  • Limit blue light exposure and stimulants (caffeine, nicotine) in the hours before bed.
  • Create a cool, dark, quiet sleep environment.
  • Incorporate regular physical activity, ideally earlier in the day.
  • Manage stress through relaxation techniques (meditation, deep breathing).

Injection Technique

General subcutaneous guidance from clinical best-practice resources[12].

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[12][13].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
  • Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms) to avoid lipohypertrophy[13].

Important Note

This content is for educational purposes only and is not medical advice.

References


  • Schoenenberger GA, Monnier M (1977)
    — Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA
    View Source

  • European Journal of Anaesthesiology (2001)
    — Delta sleep-inducing peptide: editorial review of mechanisms and clinical context
    View Source

  • Schneider-Helmert D, Schoenenberger GA (1983)
    — Effects of DSIP in man: multifunctional psychophysiological properties. Neuropsychobiology
    View Source

  • Sudakov KV et al. (2004)
    — Delta-sleep-inducing peptide sequelae: stress protective effect. Ann N Y Acad Sci
    View Source

  • Schneider-Helmert D (1981)
    — Acute and delayed effects of DSIP on human sleep behavior. Int J Clin Pharmacol Ther Toxicol
    View Source

  • Graf MV, Kastin AJ (1984)
    — Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev
    View Source

  • Iyer KS et al. (1988)
    — Sleep-inducing effect of low doses of DSIP in rats. Indian J Exp Biol
    View Source

  • Manning MC et al. (2010)
    — Stability of protein pharmaceuticals: an update. Pharm Res
    View Source

  • Wang W (2000)
    — Lyophilization and development of solid protein pharmaceuticals. Int J Pharm
    View Source

  • Yehuda S, Carasso RL (1988)
    — DSIP: brain mechanisms and function. Int J Neurosci
    View Source

  • Khvatova EM et al. (2003)
    — Delta sleep-inducing peptide: effect on oxidative stress in brain during different models. Biull Eksp Biol Med
    View Source

  • CDC
    — Vaccine administration: subcutaneous route (angle/site; no aspiration)
    View Source

  • NCBI Bookshelf
    — Medication Administration: Subcutaneous Injections (Open RN Nursing Skills)
    View Source

  • Pure Lab Peptides
    — DSIP (5 mg) product page (quality and batch documentation)
    View Source